Basics bluebird bio, Inc. Common Stock bluebird bio Inc is a clinical-stage biotechnology company which develops gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. IPO Date: June 19, 2013 Sector: Healthcare Industry: Biotech Market Cap: $39.65M Activated in VL: True Average Daily Range Avg Daily Range: $1.47 | 3.16% Avg Daily Range (30 D): $0.16 | 3.68% Avg Daily Range (90 D): $0.21 | 3.54% Institutional Daily Volume Avg Daily Volume: 1.98M Avg Daily Volume (30 D): .34M Avg Daily Volume (90 D): .31M Trade Size Avg Trade Size (Sh.): 173 Avg Trade Size (Sh.) (30 D): 144 Avg Trade Size (Sh.) (90 D): 127 Institutional Trades Total Inst.Trades: 5,458 Avg Inst. Trade: $3.1M Avg Inst. Trade (30 D): $.76M Avg Inst. Trade (90 D): $.76M Avg Inst. Trade Volume: .01M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.07M Avg Closing Trade (30 D): $.73M Avg Closing Trade (90 D): $.73M Avg Closing Volume: 9.19K         News Apr 4, 2025 @ 7:07 PM Deal Dispatch: US M&A Is Quiet, But Abroad? Volume... Source: Anthony Noto Mar 31, 2025 @ 7:49 PM BlueBird Shares Are Up Today: What's Going On? Source: Vaishali Prayag Mar 31, 2025 @ 3:24 PM Gene Therapy-Focused Bluebird Bio Receives Rival T... Source: Vandana Singh Mar 11, 2025 @ 2:17 PM Bristol Myers Squibb Scoops Up Its Blood Cancer Dr... Source: Vandana Singh Feb 21, 2025 @ 1:53 PM What's Going On With Gene Therapy Company Bluebird... Source: Nabaparna Bhattacharya Financials   TTM Q4 2024 FY 2024 Basic EPS $-24.84 $-23.74 $-24.84 Diluted EPS $-24.84 $-23.74 $-24.84 Revenue $ 83.81M $ 38.52M $ 83.81M Gross Profit $ -5.57M $ 15.73M $ -5.57M Net Income / Loss $ -240.72M $ -28.71M $ -240.72M Operating Income / Loss $ -270.46M $ -36.46M $ -270.46M Cost of Revenue $ 89.38M $ 22.79M $ 89.38M Net Cash Flow $ -168.65M $ -12.71M $ -168.65M PE Ratio     Splits Dec 13, 2024:   20:1